| Literature DB >> 28389636 |
Qian Wang1, Hongkai Yan2, Gang Wang1, Zhaoyan Qiu3, Bin Bai4, Shiqi Wang4, Pengfei Yu4, Quanxin Feng4, Qingchuan Zhao5, Xianli He6, Chaoxu Liu7,8.
Abstract
Fatty liver (FL) is one of the risk factors for acute pancreatitis and is also indicative of a worse prognosis as compared to acute pancreatitis without fatty liver (AP). The aim of the present study was to analyze, at the hepatic level, the differentially expressed genes (DEGs) between acute pancreatitis with fatty liver (APFL) rats and AP rats. GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses of these DEGs indicated that PPARα signalling pathway and fatty acid degradation pathway may be involved in the pathological process of APFL, which indicated that fatty liver may aggravate pancreatitis through these pathways. Moreover, the excessive activation of JAK/STAT signaling pathway and toll-like receptor signaling pathway was also found in APFL group as shown in heat map. In conclusion, the inhibition of PPARα signaling pathway and the fatty acid degradation pathway may lead to the further disorder of lipid metabolism, which can aggravate pancreatitis.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28389636 PMCID: PMC5429720 DOI: 10.1038/s41598-017-00821-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Experimental flow graph. Step 1: Model induction and liver collection; Step 2: RNA-seq analysis of DEGs between APFL and AP group; Step 3: GO and KEGG analysis of DEGs between APFL and AP.
Figure 2Tissue morphology in APFL and AP models. H&E staining: liver structure of rats in AP group (a) and APFL group (b); pancreas structure in AP (c) and APFL (d) group.
Figure 3Differentially expressed genes between APFL and AP. Red spots represented up-regulated genes, and green spots down-regulated genes. Black spots indicate genes that were not differentially expressed between the two samples.
List of representative dysregulated genes between APFL and AP.
| Gene name | Description | Log2 (Fold change) | Functions | Significance (P-value) |
|---|---|---|---|---|
| Log2 (APFL/AP) | ||||
| RT1-A3 | Uncharacterized protein | 18.07504 | Positive regulation of T cell mediated cytotoxicity | Yes (1.32E-05) |
| MSC | Musculin | 12.34538 | Negative regulation of transcription from RNA polymerase II promoter | Yes (9.45E-04) |
| FBXO27 | F-box protein 27 | 11.24744 | Glycoprotein binding | Yes (1.76E-07) |
| MSX1 | Msh homeobox 1 | 10.72489 | Negative regulation of cell growth | Yes (3.39E-04) |
| RGD1561212 | Similar to RIKEN cDNA | 10.69475 | Exhibits retinoic acid receptor binding | Yes (1.46E-07) |
| SIGLEC8 | Sialic acid binding Ig-like lectin 8 | 9.65489 | Intracellular signal transduction | Yes (2.15E-05) |
| RAMP3 | Receptor (G protein-coupled) activity modifying protein 3 | 9.49772 | Regulation of G-protein coupled receptor protein signaling pathway | Yes (3.41E-18) |
| ZFYVE28 | Zinc finger, FYVE domain containing 28 | 9.45763 | Negative regulation of epidermal growth factor | Yes (7.88E-09) |
| TNFAIP6 | Tumor necrosis factor alpha induced protein 6 | 9.33946 | Negative regulation of inflammatory response | Yes (1.36E-06) |
| AOC1 | Amine oxidase, copper containing 1 | 9.18586 | Amine metabolic process | Yes (1.03E-04) |
| TNN | Tenascin N | 8.82202 | Cell-matrix adhesion | Yes (4.54E-07) |
| PTX3 | Pentraxin 3 | 8.80702 | Innate immune response | Yes (1.73E-06) |
| LMX1A | LIM homeobox transcription factor 1 alpha | 8.36729 | Regulation of transcription, DNA-templated | Yes (1.65E-04) |
| RASEF | RAS and EF hand domain containing | 7.90165 | Rab protein signal transduction | Yes (1.77E-04) |
| LOC497963 | Similar to Nitric oxide synthase | 7.78913 | Nitric oxide biosynthetic process | Yes (2.15E-03) |
| DGKH | Diacylglycerol kinase | 7.55722 | Protein oligomerization | Yes (4.43E-06) |
| SLC7AL1 | Solute carrier family 7, member 11 | 7.18928 | Response to oxidative stress | Yes (7.32E-06) |
| DNM3 | Dynamin 3 | 5.22016 | Anatomical structure development | Yes (1.46E-07) |
| LRRC8E | Leucine rich repeat containing 8 family | 5.07676 | Ion transport | Yes (2.36E-06) |
| VWA2 | Von Willebrand factor A domain containing 2 | 4.13783 | Regulation of insulin receptor signaling pathway | Yes (2.53 E-03) |
| EGR2 | Early growth response 2 | 4.11453 | Cellular protein modification process | Yes (5.49 E-06) |
| FOSL2 | Fos-like antigen 2 | 4.03226 | Positive regulation of fibroblast proliferation | Yes (1.49 E-03) |
| TREM1 | Triggering receptor expressed on myeloid cells 1 | 3.94884 | Neutrophil chemotaxis | Yes (3.92 E-03) |
| FOSL1 | Fos-like antigen 1 | 3.30191 | Neurological system process | Yes (1.80 E-05) |
| GAS1 | Growth arrest-specific 1 | 2.79755 | Negative regulation of mitotic cell cycle | Yes (1.10E-20) |
| WDR4 | WD repeat domain 4 | 1.30914 | tRNA methylation | Yes (8.61E-03) |
| PTPRM | Protein tyrosine phosphatase, receptor type, M | −1.0036 | Peptidyl-tyrosine dephosphorylation | Yes (1.55 E-04) |
| CDKN1C | CDKI protein long isoform | −1.71620 | Cell cycle arrest | Yes (6.87 E-03) |
| UBD | Ubiquitin D | −2.32347 | Protein ubiquitination | Yes (2.83E-06) |
| RGMA | Repulsive guidance molecule family member A | −2.87523 | Negative regulation of collateral sprouting | Yes (8.81E-19) |
| BRDT | Bromodomain, testis-specific | −2.90388 | Chromatin remodeling | Yes (4.13 E-03) |
| CD8A | CD8a molecule | −3.37913 | Response to stress | Yes (6.91E-06) |
| FOXH1 | Forkhead box H1 | −3.95036 | Anatomical structure development | Yes (9.49E-23) |
| PDE3A | Phosphodiesterase 3A | −4.67631 | Small molecule metabolic process | Yes (4.37E-06) |
| TFF3 | Tff3 molecule | −4.82677 | Regulation of glucose metabolic process | Yes (5.44E-04) |
| OTOGL | Otogelin-like | −6.85145 | Sensory perception of sound | Yes (6.46 E-04) |
| NPR3 | Natriuretic peptide receptor 3 | −8.79741 | Negative regulation of adenylate cyclase activity | Yes (1.81E-03) |
| LOC100360055 | Cytochrome P450 2B15-like | −9.82802 | Xenobiotic metabolic process | Yes (8.93E-05) |
| MMD2 | Monocyte to macrophage differentiation -associated 2 | −10.26003 | Protein phosphorylation | Yes (2.30E-08) |
| CML3 | Camello-like 3 | −10.90368 | Gastrulation with mouth forming second | Yes (1.13E-13) |
| ALDH1A7 | Aldehyde dehydrogenase family 1 | −13.13943 | Oxidation-reduction process | Yes (3.74E-28) |
Figure 4GO classification of DEGs between APFL and AP. The x-axis indicated the subcategories, the left y-axis represented the percentage of a specific category of DEGs and the right y-axis indicated the number of DEGs.
Figure 5Scatter plot for KEGG enrichment results. The top 10 enrichment pathways are shown in the senior bubble chart. The Rich factor is the ratio of DEGs numbers annotated in this pathway term to all gene numbers annotated in this pathway term. A Q value is the corrected p value.
Figure 6DEGs related to fatty acid degradation and PPARα signaling pathway between APFL and AP. KEGG pathway maps for (a) fatty acid degradation pathway (ko00071) and (b) PPARα signaling pathway (ko03320)[49]. Up-regulated genes are marked with red borders and down-regulated genes with green borders. Non-change genes are marked with black borders. Physiological function of the peroxisome proliferator activated receptors (PPARs) is shown in (c).
Figure 7Cluster analysis of DEGs annotated in pathways associated with lipid metabolism and inflammation. The heatmap shows the expression levels of DEGs between APFL group and AP group. Transcript levels of genes encoding components involved in lipid metabolism were marked with an asterisk (*), insulin signaling pathway were marked with an asterisk (), JAK/STAT signaling pathway were marked with an asterisk (), endoplasmic reticulum stress were marked with an asterisk (), chemokine receptors were marked with an asterisk (), tumor necrosis factor receptor superfamily were marked with an asterisk (), interleukin were marked with an asterisk () and toll-like receptors were marked with an asterisk ().
Figure 8Quantitative RT-PCR validation of the selected dysregulated genes associated with fatty acid degradation. The expression levels of PPARα (a), ACSL1 (b), CPT1A (c), EHHADH (d), ACAA1A (e), ACADM (f), ACADSB (g), ALDH1B1 (h) and HADH (i) in NC, AP, FL and APFL were validated using qRT-PCR. The bar graph shows the expression of each gene in AP, FL, APFL relative to the average expression levels in NC. All error bars indicated S.D. *P < 0.05 vs NC, **P < 0.01 vs NC, # P < 0.05 vs FL.
Figure 9Linear regression analysis of fold change data between qRT-PCR and RNA-seq. Black dots represent log2 transformed fold change values of a single gene in APFL sample obtained from qRT-PCR (X-axis) and RNA-seq analysis (Y-axis). R: correlation coefficient.
Figure 10The schematic diagram of fatty liver aggravates pancreatitis. Fatty liver may aggravate pancreatitis by affecting lipid metabolism. The disorders of fatty acids degradation pathway and PPARα signaling pathway are involved in the course of APFL. Fatty liver may inhibit these two pathways to aggravate lipid metabolism disorder, which may further aggravate pancreatitis.